AlphAIAlphAI — Financial news for AI agents
en.cibercuba.comSEP 193 min read$MRNA

The first mRNA-based flu vaccine has arrived at pharmacies in the U.S.: Who can receive it?

Moderna's mRNA-based flu vaccine, mFlusiva, is now available at U.S. pharmacies like CVS for adults 50+. FDA approved it in August, with traditional and accelerated authorizations for different age groups. Clinical trials showed 27% higher efficacy than standard vaccines, with mild side effects. Costs around $171 per dose without insurance, coverage by insurers uncertain. Moderna's combined flu-COVID vaccine is not yet approved in the U.S.

Original reporting
en.cibercuba.com
Published Sep 19, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
The first mRNA-based flu vaccine has arrived at pharmacies in the U.S.: Who can receive it? — source image
Source · en.cibercuba.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The approval adds a new revenue stream and validates mRNA platform beyond COVID‑19, likely supporting a higher valuation.

02

Market read

Regulatory approval and immediate market launch create a fresh catalyst for Moderna's stock and may influence the vaccine sector.

03

What to watch

Potential competition from upcoming combined flu‑COVID mRNA vaccine in the EU may affect long‑term demand.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Moderna's mFlusiva is the first mRNA‑based influenza vaccine, approved for adults 50+ and now stocked at CVS and soon Walgreens.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

FDA approved Moderna's mFlusiva mRNA flu vaccine and it is now arriving at U.S. pharmacies.

Expected impact

Potential short-term upside as investors price in new product revenue.

Evidence & confidence

First report of FDA approval and immediate distribution; biotech approvals historically move stocks sharply.

Market effects

Sector

May accelerate adoption of mRNA technology in vaccines, benefiting the broader biotech sector.

Regional

U.S. flu vaccine market sees new entrant, could pressure traditional flu vaccine makers.

Global

First mRNA flu vaccine in the U.S.; could set precedent for other markets.

Counterpoint

What could challenge this read

If insurance coverage is delayed, uptake could be slower, limiting near‑term revenue.

Key entities

  • Company
    Moderna

    Biotech firm developing the mFlusiva vaccine.

  • Regulator
    FDA

    U.S. agency that granted approval for mFlusiva.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 18
$MRNAMedAI 8/10

The first mRNA flu shot is now available. Here’s who can get it.

Moderna's mRNA flu vaccine, mFlusiva, is now available in the U.S. for people 50 and older. It was approved after a trial showed 27% higher effectiveness than standard flu shots. The FDA approved it for adults 50-64 and accelerated approval for those 65+. Insurance coverage varies, with Medicare covering it and private insurers expected to, but Medicaid coverage is uncertain. The vaccine is priced at around $171 per dose without insurance. Pharmacies like CVS and Walgreens are beginning to stock

nbcnews.com3 min
SEP 17
$MRNAHighAI 8/10

MRNA Looks 558.1% Overvalued on GF Value™

Moderna Inc. (MRNA) shares rose 9% to $158.07 on positive Phase 3 oncology trial results, adding to a 177% surge since August. The company's P/S ratio is 28, well above its historical median and industry norms, indicating high growth expectations. Moderna's GF Value™ suggests it is 558.1% overvalued, with a GF Score™ of 58 out of 100, reflecting mixed fundamentals. Insiders sold $64.6 million in shares, while institutional activity is mixed.

gurufocus.com2 min
SEP 17
$MRNAMed

Moderna stock rises 8%: can it continue its cancer vaccine success rally?

Moderna's stock rose 8% after positive Phase 3 results for its personalized mRNA cancer vaccine, intismeran autogene, in combination with Merck's Keytruda. The trial showed improved recurrence-free survival in high-risk melanoma patients. Analysts have raised price targets, with Argus setting a $180 target. Moderna's stock has gained over 100% in the past month. Merck may also benefit from increased Keytruda demand.

invezz.com7 min
SEP 17
$MRNAMed

Why Are Moderna (MRNA) Shares Soaring Today

Moderna (MRNA) shares rose 7.1% after a positive presentation at the Morgan Stanley Global Healthcare Conference. Investors reacted to progress in its cancer vaccine trial and regulatory approvals in its respiratory portfolio. The stock is up 404% year-to-date but remains 10.8% below its 52-week high.

financialcontent.com2 min